EXOZYMES INC. (EXOZ) EBITDA
- 2026-06-30: Basis Reported; EBITDA (m); Operating income -$2.95M; Depreciation and amortization (m).
- 2026-03-31: Basis Reported; EBITDA (m); Operating income -$2.39M; Depreciation and amortization (m).
- 2025-09-30: Basis Reported; EBITDA (m); Operating income -$2.52M; Depreciation and amortization (m).
- 2025-06-30: Basis Reported; EBITDA (m); Operating income -$2.55M; Depreciation and amortization (m).
Historical EBITDA
EBITDA 3 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | Reported | (m) | -$2.95M | (m) | (m) | (m) | -$1.00* | -$1.64M* | (m) | $1.44M | (m) | (m) |
| 2026-03-31 | Reported | (m) | -$2.39M | (m) | (m) | (m) | $57.60K | -$1.52M | (m) | $1.12M | (m) | (m) |
| 2025-09-30 | Reported | (m) | -$2.52M | (m) | (m) | (m) | $13.31K* | -$1.86M* | (m) | $1.22M | (m) | (m) |
| 2025-06-30 | Reported | (m) | -$2.55M | (m) | (m) | (m) | $50.57K* | -$1.54M* | (m) | $802.99K | (m) | (m) |
| 2025-03-31 | Reported | (m) | -$1.95M | (m) | (m) | (m) | $31.05K | -$1.13M | (m) | $575.02K | (m) | (m) |
| 2024-09-30 | Reported | (m) | -$1.61M | (m) | (m) | (m) | $0.00* | -$541.52K* | (m) | $723.49K | (m) | -$1.00* |
| 2024-06-30 | Reported | (m) | -$1.33M | (m) | (m) | (m) | $37.24K* | -$2.54M* | (m) | $237.40K | (m) | $2.14K |
| 2024-03-31 | Reported | (m) | -$1.01M | (m) | (m) | (m) | $148.81K | $281.20K | (m) | $277.58K | (m) | (m) |
| 2023-09-30 | Reported | (m) | -$391.85K | (m) | (m) | (m) | (m) | (m) | (m) | $27.94K | (m) | (m) |
EBITDA 12 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | Reported | (m) | -$9.72M | (m) | (m) | (m) | $169.92K | -$6.50M | (m) | $3.71M | (m) | -$105.20K |
| 2024-12-31 | Reported | (m) | -$5.93M | (m) | (m) | (m) | $396.45K | -$8.51M | (m) | $1.87M | (m) | (m) |
| 2023-12-31 | Reported | (m) | -$1.80M | (m) | $70.07K | (m) | $288.71K | -$1.18M | (m) | $527.48K | (m) | $42.27K |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |